Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroblastoma and SCLC Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MYCN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MYCN Recombinant Protein (bHLH-LZ Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for PPI and SPR binding assays. |
View MYCN Products |
| Gene Delivery | MYCN Promise-ORF / Lentivirus Full-length ORF for stable cell line construction, reporter gene assays, and overexpression validation. |
View MYCN Products |
| Benchmark Ab | Anti-MYCN Recombinant Antibody Recombinant positive control validated for Western Blot, ChIP, and immunoprecipitation assays. |
View MYCN Products |
| Validator | MYCN siRNA Set For knockdown verification and functional rescue assays in target cell lines. |
View MYCN Products |
| Related Target A | AURKA (Aurora Kinase A) Stabilizes MYCN by preventing SCF-Fbxw7-mediated degradation. Crucial target for indirect MYCN inhibition. |
View AURKA Products |
| Related Target B | MAX Obligate heterodimerization partner of MYCN. Essential for DNA-binding and transcriptional activity. |
View MAX Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Targeting "Undruggable" Transcription Factor PPIs | Highly stable, sequence-verified MYCN and MAX recombinant proteins available for robust in vitro dimerization assays. |
| Selectivity Screening against c-Myc (MYC) | Homolog panel proteins (MYCN vs. c-Myc) strictly verified by mass spectrometry and SDS-PAGE to ensure precise off-target profiling. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and high-affinity positive control antibodies included in the portfolio. |
| False Positives | Validated siRNA sets included for sequence-specific knockdown verification in cell-based phenotypic assays. |
Live MYCN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MYCN therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to targeted protein degradation (PROTACs/molecular glues) and synthetic lethality strategies. As first-generation indirect therapies (such as Aurora Kinase A and BET inhibitors) reach clinical evaluation, the next wave of R&D is targeting direct MYCN-MAX disruption and E3-ligase-mediated degradation to overcome the historical "undruggable" barrier in MYCN-amplified malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degraders | Arvinas, Dunad Therapeutics | Neuroblastoma, NEPC, SCLC | Degradation kinetics & ternary complex validation (Need high-purity MYCN & E3 ligase complexes) |
| PPI Inhibitors | Vicore Pharma, Academic Consortia | Solid Tumors, Medulloblastoma | Dimerization disruption assays (Need high-purity MYCN and MAX proteins) |
| Indirect Inhibitors (AURKA) | AstraZeneca, Eli Lilly | SCLC, Advanced Solid Tumors | Stabilization & phosphorylation assays (Need active AURKA kinase and MYCN substrate) |